Rein Therapeutics, Inc.

Rein Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for fibrotic and other serious lung diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis and LTI-01 for lung-related indications, with development activities conducted through clinical research partners and external manufacturing and regulatory support.

0.70

— Rein Therapeutics, Inc.
	%
LTI-03	0% Inhaled peptide candidate being developed for idiopathic pulmonary fibrosis.
LTI-01	0% Earlier-stage lung disease product candidate in the company pipeline.
Clinical development services	45% Outsourced clinical trial execution, monitoring, and study operations for pipeline programs.
Preclinical and nonclinical development	25% Animal studies, toxicology work, and supporting research required before and during trials.
Regulatory and CMC support	30% Regulatory consulting, manufacturing, and clinical supply activities tied to development.

Rein Therapeutics does not sell commercial products; its primary counterparties are clinical research organizations,...

Clinical research organizationsprimary
They perform trial management and study execution for LTI-03 and other programs.
Manufacturing and development vendorsprimary
They supply clinical materials, testing, and development support needed for trials.
Regulatory authoritiesprimary
They review safety, toxicology, and clinical data needed to advance candidates.
Potential licensing partnerssecondary
They may acquire or license non-core assets such as oncology programs.
Future pulmonary care providers and patientsemerging
They would use approved therapies for fibrotic lung disease and related indications.

Rein Therapeutics is headquartered in the United States and conducts most of its development and corporate activities...

•United States is the corporate base and a core clinical market
•FDA oversight is central to U.S. trial progression
•Australia is used for trial activation and patient enrollment
•United Kingdom sites support international clinical development
•Europe provides additional trial access and diversification

The company’s strategy is to advance LTI-03 and LTI-01 through preclinical and clinical development while expanding its...

Advance LTI-03 clinical developmentshort-term

LTI-03 is the lead asset and the main driver of future value creation.

Expand and diversify the pipelinemedium-term

Additional candidates reduce dependence on a single program and broaden optionality.

Maintain external development infrastructureshort-term

Outsourced CRO, manufacturing, and regulatory support are essential to move programs forward.

The company faces high clinical and regulatory risk because its value depends on successful trial execution,...

critical

FDA clinical hold on LTI-03

The lead Phase 2 trial was placed on hold pending additional nonclinical work.

Scope: LTI-03 RENEW Phase 2 trial
Materiality: high

high

Clinical development failure

Drug candidates may not demonstrate safety, tolerability, or efficacy in humans.

Scope: LTI-03 and LTI-01
Materiality: high

high

Financing risk

The company needs external capital to fund trials, manufacturing, and operations.

Scope: Corporate liquidity and development programs
Materiality: high

medium

Third-party execution risk

Clinical and manufacturing work is outsourced and depends on vendor performance.

Scope: CROs, manufacturers, consultants
Materiality: medium

medium

Intellectual property and partnering risk

Value depends on protecting assets and maintaining collaboration or licensing options.

Scope: Pipeline assets and future commercialization
Materiality: medium

Research and development accruals

Can shift quarterly R&D expense materially

Clinical supply inventory and write-offs

Can create one-time expense spikes

Warrants and equity financing

Affects equity, earnings per share, and capital structure

Contingent consideration and partnering fees

Can affect other income, liabilities, or future cash flows

Rein Therapeutics, Inc.

FDA clinical hold on LTI-03

Clinical development failure

Financing risk

Third-party execution risk

Intellectual property and partnering risk

Relay Therapeutics, Inc.

Vera Therapeutics, Inc.

INSMED Inc

Century Therapeutics, Inc.

AIM ImmunoTech Inc.

RenovoRx, Inc.